Welcome to our dedicated page for Nexalin Technology Warrant news (Ticker: NXLIW), a resource for investors and traders seeking the latest updates and insights on Nexalin Technology Warrant stock.
Nexalin Technology Inc. offers a drug-free therapy for anxiety, depression, and insomnia. The patented waveform of the Nexalin device provides transcranial electrical stimulation, resulting in increased beta-endorphins and balance in the brain's neurochemistry.
The FDA-approved Gen-1 device uses bioelectronic medical technology to treat anxiety and insomnia without drugs. Nexalin's neurostimulation products aim to combat the global mental health epidemic with safe and effective solutions.
The company's innovative Gen-3 HALO™ Clarity Virtual Clinic model and growing clinical data support the efficacy of its therapy. With extensive safety analysis and FDA approval, Nexalin is a leader in non-invasive mental health treatment.
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) provided a business update on March 27, 2023, highlighting progress in clinical trials for new neurostimulation devices aimed at treating mental health disorders. The Gen-2 and Gen-3 devices are expected to improve treatment efficacy without medication. Revenue for 2022 reached $1.3 million, a significant increase from $0.1 million in 2021, primarily due to more device sales. While operating expenses decreased to $2.8 million from $6.1 million, the net loss narrowed to $1.7 million per share. The company reports having $7.0 million in liquidity for future operations.
Nexalin Technology announced the appointment of Michael Nketiah as Senior Vice President of Quality, Clinical, and Regulatory. Nketiah brings over 23 years of experience in regulatory affairs and clinical operations, specifically with the FDA. His expertise will support the company in accelerating FDA clearance for its Generation 2 and Generation 3 neurostimulation devices, aimed at improving healthcare outcomes for mental and neurodegenerative illnesses. The Gen-2 device is designed to penetrate deeper into the brain using an advanced waveform, while the Gen-3 prototype will utilize a virtual-clinic model for treatment.
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) provided a business update emphasizing its advancements in neurostimulation devices aimed at combating mental health disorders. The company is enhancing its Gen-1 device to a more powerful Gen-2 model with a waveform increase from 4 milliamps to 15 milliamps, expected to improve treatment efficacy. Plans for FDA submissions and clinical trials are outlined, including a strategy for addressing Major Depressive Disorder. Additionally, Nexalin reports progress with its devices in China and a recent white paper supporting its technology's effectiveness for anxiety treatment.
Nexalin Technology, Inc. (NXL, NXLIW) announced positive results from a white paper published by the Second Xiangya Hospital, documenting the effectiveness of its tACS device for treating generalized anxiety disorder. The study reported complete disappearance of somatic anxiety symptoms and improved sleep quality in a patient after a 10-day treatment regimen. The benefits persisted for four months, indicating the device's potential in addressing mental health issues without side effects. The company aims to expand its clinical research and treatment applications in the mental health field.
Nexalin Technology, Inc. has successfully closed its initial public offering of 2,315,000 units, each unit comprising one share of common stock and one warrant, at an offering price of $4.15 per unit. This translates to gross proceeds of approximately $9.6 million before expenses. Trading commenced on The Nasdaq Capital Market under the symbols ‘NXL’ for shares and ‘NXLIW’ for warrants on September 16, 2022. The company has also granted underwriters a 45-day overallotment option for additional securities.
FAQ
What is the current stock price of Nexalin Technology Warrant (NXLIW)?
What does Nexalin Technology Inc. offer?
What is the patented waveform technology of the Nexalin device?
How does the Gen-1 device work?
What is the Gen-3 HALO™ Clarity Virtual Clinic model?
Is Nexalin FDA-approved?
What makes Nexalin a leader in mental health treatment?
What clinical data supports Nexalin's therapy?
How does Nexalin's therapy differ from traditional treatments?